Extrawell Pharmaceutical Holdings Limited

Extrawell Pharmaceutical Holdings Limited

HHKEX:858
0.06
HKD
+0.00
(+3.77%)
290.70MMarket Cap
Extrawell Pharmaceutical Holdings Limited
HKEX:858
(Hong Kong Exchange)

Recent

price

0.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
HKD
0.09
0.09
0.07
0.07
0.06
0.05
0.06
0.05
0.04
0.04
0.03
0.03
0.03
0.03
0.02
0.02
- -
Revenue per Share
0.01
0.01
0.01
- -
0.01
0.23
0.01
0.01
0.01
0.03
0.03
-0.05
0.05
0.05
-0.07
0.09
- -
Basic EPS, GAAP
0.01
- -
- -
-0.01
-0.03
-0.01
- -
- -
- -
-0.01
-0.01
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.15
0.15
0.16
0.17
0.18
0.42
0.43
0.43
0.45
0.45
0.48
0.43
0.49
0.54
0.47
0.56
0.35
Book Value per Share
0.02
0.03
0.04
0.04
0.06
0.41
0.42
0.43
0.44
0.44
0.48
0.43
0.49
0.54
0.46
0.56
0.35
Tangible Book Value per Share
2,290
2,290
2,290
2,290
2,355
2,390
2,390
2,390
2,390
2,390
2,390
2,390
2,390
2,390
2,390
2,390
2,399
Basic Weighted Avg Shares
196
199
157
151
151
129
142
108
86
89
78
79
74
73
59
55
- -
Sales/Revenue/Turnover
9.32
2.57
4.29
6.64
-6.31
-22.19
-5.97
-13.73
-19.87
-18.73
-16.08
-11.08
-16.84
-16.24
-10.75
-16.08
- -
Operating Margin (%)
6
4
4
3
3
6
6
7
7
7
6
8
9
9
9
8
- -
Depreciation Expense
15
12
20
11
14
555
33
21
30
64
83
-121
131
129
-163
223
- -
Net Income, GAAP
- -
20.67
5.49
7.95
55.09
- -
0.33
3.25
- -
0.08
- -
- -
0.94
0.86
- -
0.52
- -
Effective Tax Rate (%)
7.45
5.82
12.97
7.2
9.17
431.03
23.05
19.27
34.9
71.77
107.34
-153.67
176.65
178.11
-275.73
401.67
- -
Profit Margin (%)
204
209
241
234
111
136
160
181
114
129
151
153
130
122
126
1,014
592
Working Capital
- -
- -
5
6
29
25
30
35
42
50
63
72
83
102
119
139
152
LT Debt
550
560
575
583
559
996
1,016
1,026
1,067
1,062
1,140
1,029
1,165
1,282
1,113
1,335
893
Total Equity
- -
0.73
1.4
1.42
3.1
- -
5.7
5.42
- -
-1.63
- -
- -
-1.78
-0.89
- -
-0.83
- -
Return on Invested Capital (%)
- -
0.73
4.37
2.32
2.59
- -
4.14
2.72
- -
6.54
- -
- -
12.17
10.95
- -
18
- -
Return on Capital (%)
4.44
3.35
5.61
2.87
3.42
78.48
3.26
2.03
2.85
5.99
7.54
-11.15
11.89
10.56
-13.61
18.19
- -
Return on Common Equity (%)

Capital Structure

HKD

•

in mil. unless spec.
Sep'25
Mar'25
Sep'26
ST Debt
1
2
1
LT Borrowings
128
139
152
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,390
2,390
2,550
Market Capitalization
79
108
291

Working Capital

HKD

•

in mil. unless spec.
Sep'25
Mar'25
Sep'26
Total Current Assets
935
1,063
641
Cash, Cash Equivalents & STI
868
995
94
Accounts Receivable, Net
7
4
10
Inventories
3
5
3
Total Current Liabilities
50
49
49
Payables & Accruals
- -
- -
- -
ST Debt
1
2
1
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.41%
4.06%
19.97%
Free Cash Flow
38.15%
105.18%
52.14%
Net Income, GAAP
-85.97%
-183.39%
-236.63%
Sales/Revenue/Turnover
-7.45%
-6.24%
-6.21%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
59
2025
- -
- -
55
2026
- -
- -
- -

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.07
2025
- -
- -
0.09
2026
- -
- -
- -

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Business
Extrawell Pharmaceutical Holdings Limited operates as an investment holding enterprise, primarily engaged in the creation, production, promotion, and distribution of pharmaceutical solutions across the People's Republic of China and Hong Kong. Its diverse operations are organized into key divisions: Manufacturing, Trading, Gene Development, and a dedicated Oral Insulin segment. Within its manufacturing arm, the company produces a range of specialty drugs, including an oral solution designed as a dual immune regulator for viral infections and weakened cellular immunity, a topical treatment for various skin issues such as radiation burns, general burns, dermatitis, and ulcers, as well as for aiding in post-operative wound recovery, and a compound that inhibits thromboxane synthetase, which helps prevent blood clotting and promotes vasodilation. The trading segment focuses on promoting and distributing a portfolio of imported pharmaceutical items, featuring treatments for hypertension and products addressing a spectrum of skin conditions like itching, redness, and scaly patches, alongside therapies for central nervous system lesions and Parkinson's disease. This division also handles imported healthcare products, nutritional items, and medical equipment, including specific pain management devices and Australian dairy products under its own brand. The gene development division is dedicated to the commercial application and advancement of genomic technologies. Furthermore, the company is actively involved in the clinical trial development of an oral insulin product for diabetes management. Complementing these core activities, Extrawell also provides agency services and maintains interests in property investments. While the company reported a significant profit turnaround for the fiscal year ending March 31, 2025, largely driven by gains from convertible bond fair value changes, it later projected an expected loss for the six months ending September 30, 2025, predominantly due to unrealized losses on similar investments. In a strategic move, Extrawell completed a new share issuance in September 2025 to facilitate diversification into the broader healthcare sector, aligning with national strategies and targeting emerging markets. The corporate headquarters are situated in Quarry Bay, Hong Kong.